Q1 2026 Earnings Estimate for STERIS plc Issued By Zacks Research (NYSE:STE)

STERIS plc (NYSE:STEFree Report) – Equities research analysts at Zacks Research raised their Q1 2026 earnings per share estimates for STERIS in a report released on Monday, April 1st. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.56 per share for the quarter, up from their prior estimate of $2.55. The consensus estimate for STERIS’s current full-year earnings is $8.67 per share.

STE has been the topic of several other research reports. Morgan Stanley lowered their price target on STERIS from $225.00 to $215.00 and set an “equal weight” rating on the stock in a report on Monday, December 4th. Stephens reiterated an “overweight” rating and set a $250.00 price target on shares of STERIS in a report on Friday, February 9th. JMP Securities reiterated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a report on Thursday, February 8th. KeyCorp started coverage on STERIS in a report on Tuesday, February 6th. They set an “overweight” rating and a $253.00 price target on the stock. Finally, TheStreet upgraded STERIS from a “c+” rating to a “b” rating in a report on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $239.60.

View Our Latest Research Report on STE

STERIS Trading Down 1.7 %

NYSE:STE opened at $221.03 on Tuesday. The stock’s 50 day moving average price is $227.17 and its 200 day moving average price is $218.93. STERIS has a 52 week low of $180.54 and a 52 week high of $254.00. The company has a market capitalization of $21.84 billion, a P/E ratio of 38.71 and a beta of 0.79. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.49 and a current ratio of 2.43.

STERIS (NYSE:STEGet Free Report) last released its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $2.22 EPS for the quarter, topping analysts’ consensus estimates of $2.17 by $0.05. STERIS had a return on equity of 13.67% and a net margin of 10.48%. The firm had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.35 billion. During the same quarter in the prior year, the company posted $2.02 earnings per share. The firm’s revenue was up 14.8% on a year-over-year basis.

Institutional Investors Weigh In On STERIS

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nomura Holdings Inc. bought a new position in STERIS in the fourth quarter worth $441,000. HighPoint Advisor Group LLC bought a new position in STERIS in the fourth quarter worth $710,000. Vanguard Group Inc. lifted its position in STERIS by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 11,864,606 shares of the medical equipment provider’s stock worth $2,608,434,000 after purchasing an additional 53,526 shares during the period. Fisher Asset Management LLC lifted its position in STERIS by 23.1% in the fourth quarter. Fisher Asset Management LLC now owns 1,222 shares of the medical equipment provider’s stock worth $269,000 after purchasing an additional 229 shares during the period. Finally, Wellington Management Group LLP bought a new position in STERIS in the fourth quarter worth $1,139,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Friday, February 23rd were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a $2.08 annualized dividend and a dividend yield of 0.94%. STERIS’s payout ratio is 36.43%.

About STERIS

(Get Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Featured Articles

Earnings History and Estimates for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.